Latest News
Feb 2023: New Hywel Dda UHB Hormone Replacement Therapy Formulary and Prescribing Information published (link
Welcome to the Inform Formulary

This electronic formulary lists all medicines approved for use in Primary and Secondary care, it includes all drug decisions by the Hywel Dda UHB Medicines Management Group, NICE & All Wales Medicines Strategy Group.

Each chapter is subject to continuous review by clinicians and pharmacists across the local area. Please email us at the address below if you would like to comment or assist with the review process.

Prescribing in Pregnancy
Recommended resources (which do not require passwords) are:

  • Royal College of Obstetricians & Gynaecologists has a range of guidelines on womens health 
Prescribing in Breastfeeding (Lactation)
For Paediatric queries please refer to the BNF for Children under each individual drug
Searching the Formulary
Where possible we have included NICE guidance and CSM warnings. Please refer to the Summary of Product Characteristics for full prescribing information.

Internet access and updates
This formulary is constantly being updated.
Thank you to all clinicians and pharmacists who have provided advice on various sections and to our clerical staff for their support.

Any comments?
We hope you will find the Hywel Dda UHB Formulary useful and that it will help you to improve patient care. Your comments and suggestions for future updates would be welcome and may be made by contacting us at the addresses below:

Contact Information
Formulary Issues: Sue Beach, Clinical Development Pharmacist, Email: 

Hywel Dda Medicines Management Group: Sue Beach, Clinical Development Pharmacist, Email:

Medicines Information Enquiries
Please contact your local hospital pharmacy or Medicines Management Team in the first instance

The Hywel Dda Medicines Information Centre is based in the Pharmacy Department, Withybush General Hospital

NB: Hywel Dda UHB Medicines Information/Gwybodaeth Meddygaeth has a new telephone number for Healthcare Professional Enquiries: 01437 773641
The existing nymber (01437 773418) is now dedicated to the Withybush Patient Medicines Information Line.
Non-urgent Medicines Information enquiries can also be submitted via:
 The email account will be checked every working day. so only send equiries by this route if you do not require an answer within 24 hours.
Please note:
The information contained in this formulary is issued on the understanding that it is the best available from the resources at our disposal at the date of compilation.

Manufacturers may alter the formulation of a product from time to time. Further information on any given product may be obtained from your Medicines Information Centre or the manufacturer. Manufacturers’ Data Sheets or Summary of Product Characteristics should be consulted for full prescribing information.

Extracts from NICE guidance have been added for general information. Please consult the full guidance before making therapeutic decisions.

Although great care has been taken to ensure the information is as up-to-date and accurate as possible, we cannot accept responsibility for any errors or omissions.
Comments on the content should be emailed to  Please email details of any problems or comments on the website to .
Key to Symbols:
1st = First Line drugs (Drugs recommended in both primary and secondary care)
2nd = Second line drugs (alternatives, often in specific conditions, in primary and secondary care)
S = Specialist initiated or recommended medicines (Secondary Care Consultant Team, GP with special interest or authorised independent prescribers). Medicines are suitable for continuation by Primary Care. Check mongraph whether recommended or initiated. Shared care agreements may apply)
H = Hospital only drugs (Drugs only suitable for secondary care use and initiated by appropriate team or specialist. Primary care prescribers should not be asked to prescribe)
NF Non-formulary
SC = Shared care protocol
D Formulary in development